Stockscreener 앱 받기
32.03
2.26%
-0.74
시간 외 거래:
32.03
전일 마감가:
$32.77
열려 있는:
$32.36
하루 거래량:
590.66K
Relative Volume:
1.13
시가총액:
$1.86B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
29.95
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
-3.38%
1개월 성능:
-0.76%
6개월 성능:
-11.45%
1년 성능:
+20.59%
1일 변동 폭
$31.89
$32.91
1주일 범위
$31.89
$33.70
52주 변동 폭
$25.53
$40.28
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
32.03 | 1.86B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
164.33 | 75.76B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.87 | 49.79B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.20 | 46.73B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.99 | 20.38B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
283.35 | 14.70B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | 재개 | Jefferies | Buy |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | 재개 | Jefferies | Hold |
| 2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
| 2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-11-12 | 재확인 | B. Riley FBR | Buy |
| 2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
| 2017-10-19 | 개시 | FBR & Co. | Buy |
| 2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | 개시 | Janney | Neutral |
| 2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-11-05 | 재확인 | Northland Capital | Outperform |
| 2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Cut by Rhumbline Advisers - Defense World
California State Teachers Retirement System Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Two Sigma Advisers LP Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LP - Defense World
Millennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
(SUPN) Trading Report - news.stocktradersdaily.com
Supernus at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Supernus (SUPN) Partners with Jay Glazer for ADHD Awareness Series | SUPN Stock News - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and R - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree - Nasdaq
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD - GlobeNewswire
Jay Glazer and Wife Share Raw ADHD Story: How Treatment Changed Their Marriage - Stock Titan
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Supernus (SUPN) to Protect Qelbree Patents Amid Generic Challenges | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Faces Patent Challenges for Qelbree - TipRanks
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference | SUPN Stock News - GuruFocus
Supernus CEO Fireside Chat: Latest CNS Pipeline Insights Coming at Major Healthcare Conference - Stock Titan
Supernus Announces Paragraph IV ANDA Filings for Qelbree® | SUPN Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Investment Report - news.stocktradersdaily.com
Bank of America Corp DE Has $13.49 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrep - GuruFocus
Busy Philipps Partners with Supernus (SUPN) to Empower Women wit - GuruFocus
Supernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHD - Nasdaq
Busy Philipps Empowers Women with ADHD to Go from Feeling - GlobeNewswire
Busy Philipps Reveals ADHD Journey: New Campaign Spotlights Hidden Women's Symptoms - Stock Titan
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Strong-Buy” at StockNews.com - Defense World
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality - simplywall.st
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.54%
자본화:
|
볼륨(24시간):